July 13, 2020

The Niche

Knoepfler lab stem cell blog

Stem Cells

3 min read

There is always plenty of complicated, mixed-bag news on the stem cell and regenerative medicine front so it’s great to highlight when there’s some good news out there. Today’s post includes several such upbeat items. At the bottom I’ve included a list of some recent interesting publications as well. Good news on vision front: jCyte Therapy Deal with Santen Pharmaceutical. David Jensen over at California Stem Cell Report reported on this blockbuster deal for a quarter of a billion dollars. Jensen wrote: “The California …Read More

3 min read

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as RMATs. As a result, the RMAT-qualified gene therapies get to go into a speedier lane of FDA oversight. Today’s post is a mix of recommended reads in the regenerative …Read More

6 min read

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do? Below I grade my 20 predictions for this year. You can in addition see my grading of my 2018 predictions here. In the next week or so I’ll also …Read More

2 min read

Once or twice a month I do a post on notable stem cell publications and news, which often but not always include research on iPS cells. It’s sort of a recommended reads kind of post, but I often include one or two things that aren’t necessarily recommended exactly yet seem kind of surprising or novel in some ways. Here’s today’s list. One bit of news first On the RMAT front: “FDA Grants RMAT Designation for CAR T-Cell Therapy for Multiple Myeloma.”  You can see …Read More